Role of Probiotics & Metabolic response in Schizophrenia- A Randomised double blind placebo controlled study

VIBRONICA A Division of Kepler heathcare Pvt Ltd0 个研究点目标入组 100 人开始时间: 待定最近更新: 2023年5月1日

试验速览

暂无简介。

•1.Patients aged 18-45 years.
•2.ICD -10 diagnosis of schizophrenia any type or schizoaffective disorder with disease duration of atleast 2 years.
•3.Willing to participate in the study
•4.Education of 9th std and above
•5.Scores on the Positive and Negative Syndrome Scale (PANSS) indicative of at least moderately severe psychosis, total PANSS score >= 50.
•6.Cognitive deficit below 15th percentile in any one cognitive domain of NIMHANS battery.

•1.Patients who are uncooperative due to the severity of the illness.
•2.Existence of serious medical/neurological disorder, known allergic to Probiotics.
•3.Patients with diagnosis of mental retardation.
•4.Primary diagnosis of substance abuse or dependence within the last 3 months.
•participated in any investigational drug trial in the past 30 days;
•5.Women who were currently pregnant, planning to get pregnant /breastfeeding.
•Not consenting to participate in the study.

发起方

VIBRONICA A Division of Kepler heathcare Pvt Ltd